suprastin
egis pharmaceuticals plc - chloropiraminas - tabletės - 25 mg - chloropyramine
bicalutamide accord
accord healthcare b.v. - bikalutamidas - plėvele dengtos tabletės - 150 mg - bicalutamide
abacavir/lamivudine viatris [abacavir/lamivudine mylan pharma]
viatris limited - abakaviras/lamivudinas - plėvele dengtos tabletės - 600 mg/300 mg - lamivudine and abacavir
ticagrelor mylan
viatris limited - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
tadalafil accord
accord healthcare b.v. - tadalafilis - plėvele dengtos tabletės - 20 mg; 10 mg; 5 mg - tadalafil
abiraterone teva
teva b.v. - abiraterono acetatas - plėvele dengtos tabletės - 500 mg - abiraterone
zyrtec
ucb pharma oy finland - cetirizino dihidrochloridas - geriamieji lašai (tirpalas) - 1 mg/ml; 10 mg/ml - cetirizine
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antinavikiniai vaistai - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
infanrix penta
glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vakcinos - infanrix penta yra skiriamas pradinei ir revakcinacijai kūdikiams nuo difterijos, stabligės, kokliušo, hepatito b ir poliomielito.